Menu
Not yet recruiting NCT07746245

The Efficacy of CAPCT in Patients With PTCL

Phase II Interventional Peripheral T-Cell Lymphoma

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Chidamide, Azacitidine (AZA), Prednisone, Cyclophosphamide.
Who it may be relevant to
Registry conditions: Peripheral T-Cell Lymphoma. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Multicenter, Single-Arm, Open-Label Clinical Study to Observe the Efficacy of Chidamide Combined With Azacitidine, Prednisone, Cyclophosphamide, and Thalidomide in Patients With Peripheral T-Cell Lymphoma (PTCL) Who Are Intolerant to Standard Chemotherapy.

Overview

This study is a multicenter, single-arm, non-randomized, open-label trial designed to evaluate the efficacy and safety of chidamide and azacitidine in combination with prednisone, cyclophosphamide, and thalidomide (CAPCT regimen) in patients with peripheral T-cell lymphoma (PTCL). A total of 58 patients with PTCL are planned to be enrolled after providing written informed consent and meeting all eligibility criteria. Enrolled patients will receive the CAPCT regimen, with each cycle consisting of 21 days, for a total of 6 cycles. Participants who do not experience disease progression or unacceptable toxicity after 6 cycles of combination therapy will continue to receive the CPCT regimen (chidamide combined with prednisone, cyclophosphamide, and thalidomide) for up to 6 months, followed by chidamide monotherapy as maintenance treatment. The primary efficacy endpoint is objective response rate (ORR).

Interventions

  • Drug Chidamide
    Chidamide tablets,：Oral administration at a dose of 20 mg (4 tablets) per intake, twice weekly, with an interval of no less than 3 days between the two doses .
  • Drug Azacitidine (AZA)
    Subcutaneous injection at a dose of 100 mg/day on Days 1-7
  • Drug Prednisone
    Oral administration at a dose of 20 mg/day, taken after breakfast.
  • Drug Cyclophosphamide
    Oral administration at a dose of 50 mg/day, taken after lunch.
  • Drug Thalidomide (100mg)
    Oral administration at a dose of 100 mg/day, taken before bedtime.

Primary outcome measures

  • Objective Response Rate（ORR） [Time frame: Up to 2 years]
Secondary outcome measures (4)
  • Duration of Response（DoR） [Time frame: Up to 2 years]
  • Progression-Free Survival（PFS） [Time frame: From treatment to the end of treatment at 12months]
  • Overall Survival（OS） [Time frame: From treatment to the end of treatment at 24 months]
  • Adverse Event [Time frame: From enrollment to the end of treatment at 24 months]

Eligibility criteria

Inclusion criteria

  • 1\. Patients with histopathologically confirmed peripheral T-cell lymphoma (PTCL), with exclusion of NK/T-cell lymphoma.
  • 2\. Patients who are treatment-naïve or have relapsed/refractory disease.
  • 3\. Patients who are intolerant to standard chemotherapy regimens for various reasons, including those aged ≥75 years, or those aged <75 years but deemed by the investigator to be unsuitable for or unable to tolerate chemotherapy.
  • 4\. Patients aged ≥18 years, male or female.
  • 5\. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-3.
  • 6\. Absolute neutrophil count ≥1.5×10⁹/L, platelet count ≥50×10⁹/L, and hemoglobin ≥70 g/L.
  • 7\. Estimated life expectancy ≥3 months.
  • 8\. Voluntary signing of written informed consent.

Exclusion criteria

  • 1\. Pregnant or lactating women, or fertile patients of childbearing potential who are unwilling to adopt contraceptive measures.
  • 2\. Patients with chronic heart failure of New York Heart Association (NYHA) functional class III or IV; or those with a history of any of the following cardiac conditions within 6 months: acute coronary syndrome; acute heart failure (NYHA functional class III or IV); or significant ventricular arrhythmias (sustained ventricular tachycardia, ventricular fibrillation, or sudden cardiac death after resuscitation).
  • 3\. Hepatic dysfunction (total bilirubin >1.5× the upper limit of normal \[ULN\]; alanine aminotransferase \[ALT\] and aspartate aminotransferase \[AST\] >2.0× ULN, or >5× ULN in patients with hepatic involvement); or renal dysfunction (serum creatinine >1.5× ULN).
  • 4\. Confirmed central nervous system (CNS) involvement by lymphoma.
  • 5\. Receipt of prior myelosuppressive symptomatic treatment within 7 days before enrollment.
  • 6\. Active hemorrhage/bleeding.
  • 7\. Patients with acquired immunodeficiency syndrome (AIDS), syphilis, or active hepatitis B (HBV DNA >1×10⁵ copies/mL) or hepatitis C.
  • 8\. Receipt of grade II or higher surgery within 3 weeks prior to treatment.
  • 9\. Psychiatric disorders or inability to provide informed consent.
  • 10\. Patients deemed by the investigator to be unsuitable for participation in this trial.
  • 11\. Known allergy to any component of the investigational drug.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

China · 1 center
  • The First Affiliated Hospital of Nanjing Medical University — Nanjing

Identifiers

NCT: NCT07746245 · 2026-SR-420

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗